Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DLG3 antisense RNA 1 (DLG3-AS1) is a long non-coding RNA (lncRNA) transcribed from the antisense strand of the DLG3 gene locus. As an antisense RNA, it does not encode a protein but may regulate the expression, splicing, and stability of its sense counterpart (DLG3) or participate in broader chromatin or epigenetic regulatory mechanisms. Antisense lncRNAs like DLG3-AS1 have been implicated in the regulation of gene expression at transcriptional and post-transcriptional levels; in some contexts, antisense lncRNAs modulate cell proliferation, differentiation, or tumorigenesis, although no direct evidence is available for DLG3-AS1 specifically[1][2][3]. Currently, DLG3-AS1 is not recognized as a direct therapeutic target, biomarker, or druggable entity. Key points: - DLG3-AS1 is classified as a non-coding, antisense lncRNA, not as a receptor, enzyme, or classical therapeutic target[1][2][3]. - There are no known drugs that interact with DLG3-AS1, and mechanisms of action for therapeutics targeting DLG3-AS1 are not reported. - DLG3-AS1’s functions and disease associations remain largely uncharacterized beyond general roles established for long non-coding antisense RNAs[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DLG3 antisense RNA 1 (DLG3-AS1).